Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation

Journal of Clinical Pharmacology

Volumn 49, Issue 9, 2009, Pages 1079-1090

  Kwara, Awewura ^a,f   Lartey, Margaret ^b   Boamah, Isaac ^b   Rezk, Naser L ^c   Oliver Commey, Joseph ^d   Kenu, Ernest ^d   Kashuba, Angela D M ^c   Court, Michael H ^e  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF GHANA   (Ghana)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d KORLE BU TEACHING HOSPITAL   (Ghana)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MIRIAM HOSPITAL   (United States)

Author keywords

Interindividual variability; NRTIs; Pharmacokinetics; Rifampin; UGT2B7

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; GLUCURONOSYLTRANSFERASE 2B7; ISONIAZID; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; MESSENGER RNA; PYRAZINAMIDE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; EVENING DOSAGE; FEMALE; GENETIC ASSOCIATION; GHANA; HETEROZYGOTE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; MORNING DOSAGE; OPTIMAL DRUG DOSE; PARAMETER; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TUBERCULOSIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; DRUGS, GENERIC; FEMALE; GHANA; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HALF-LIFE; HIV INFECTIONS; HUMANS; LAMIVUDINE; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TUBERCULOSIS; ZIDOVUDINE;

EID: 69549103001     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009338482     Document Type: Article

References (41)

1. US Department of Health and Human Services (DHHS) Panel on Antiretroviral Guideline for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. November 2008. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 10, 2009.
2. Hammer SM, Eron JJ Jr, Reiss P., et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008 ; 300: 555-570.
3. World Health Organization (WHO). Antiretroviral Therapy for HIV Infection in Adults and Adolescents in Resource-Limited Settings: Towards Universal Access. Geneva, Switzerland: WHO ; 2006. http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf. Accessed January 10, 2009.
4. Anderson PL, Lamba J., Aquilante CL, Schuetz E., Fletcher CV Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 ; 42: 441-449.
5. Burger DM, Meenhorst PL, Koks CH, Beijnen JH Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother. 1993 ; 37: 1426-1431.
6. Gallicano KD, Sahai J., Shukla VK, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol. 1999 ; 48: 168-179.
7. Hoetelmans RM Pharmacology of antiretroviral drugs. Antivir Ther. 1999 ; 4 (suppl 3). 29-41.
8. Horton CM, Dudley MN, Kaul S., et al. Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother. 1995 ; 39: 2309-2315.
9. Johnson MA, Moore KH, Yuen GJ, Bye A., Pakes GE Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999 ; 36: 41-66.
10. Panhard X., Legrand M., Taburet AM, Diquet B., Goujard C., Mentre F. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART. Eur J Clin Pharmacol. 2007 ; 63: 1019-1029.
11. Byakika-Kibwika P., Lamorde M., Kalemeera F., et al. Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2008 ; 62: 1113-1117.
12. Hosseinipour MC, Corbett AH, Kanyama C., et al. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. AIDS. 2007 ; 21: 59-64.
13. Kwara A., Lartey M., Sagoe KW, et al. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV coinfected patients: pharmacogenetic effect of CYP2B6 variation. J Clin Pharmacol. 2008 ; 48: 1032-1040.
14. Lopez-Cortes LF, Ruiz-Valderas R., Viciana P., et al. Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet. 2002 ; 41: 681-690.
15. Gurumurthy P., Ramachandran G., Hemanth Kumar AK, et al. Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. Clin Infect Dis. 2004 ; 38: 280-283.
16. Sahai J., Gallicano K., Swick L., et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med. 1997 ; 127: 289-293.
17. Kullak-Ublick GA, Becker MB Regulation of drug and bile salt transporters in liver and intestine. Drug Metab Rev. 2003 ; 35: 305-317.
18. Schuetz JD, Connelly MC, Sun D., et al. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 1999 ; 5: 1048-1051.
19. Corpechot C., Ping C., Wendum D., Matsuda F., Barbu V., Poupon R. Identification of a novel 974Cĝ†'G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. Am J Gastroenterol. 2006 ; 101: 2427-2432.
20. Barbier O., Turgeon D., Girard C., et al. 3ĝ€2-azido- 3ĝ€2-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab Dispos. 2000 ; 28: 497-502.
21. Mentre F., Escolano S., Diquet B., Golmard JL, Mallet A. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. Eur J Clin Pharmacol. 1993 ; 45: 397-407.
22. Pacifici GM, Evangelisti L., Giuliani L., Metelli RM, Giordani R. Zidovudine glucuronidation in human liver: interindividual variability. Int J Clin Pharmacol Ther. 1996 ; 34: 329-334.
23. Court MH, Krishnaswamy S., Hao Q., et al. Evaluation of 3ĝ€2-azido-3ĝ€2-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos. 2003 ; 31: 1125-1133.
24. Innocenti F., Liu W., Fackenthal D., et al. Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics. 2008 ; 18: 683-697.
25. Rezk NL, Tidwell RR, Kashuba AD Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 ; 791: 137-147.
26. Hesse LM, He P., Krishnaswamy S., et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics. 2004 ; 14: 225-238.
27. Holthe M., Rakvag TN, Klepstad P., et al. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 2003 ; 3: 17-26.
28. Saeki M., Saito Y., Jinno H., et al. Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos. 2004 ; 32: 1048-1054.
29. Vezina HE, Henry K., Ravindran GD, et al. A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India. J Acquir Immune Defic Syndr. 2006 ; 41: 131-136.
30. Chatton JY, Munafo A., Chave JP, et al. Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol. 1992 ; 34: 551-554.
31. Lee BL, Safrin S., Makrides V., Gambertoglio JG Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1996 ; 40: 1231-1236.
32. Peterkin VC, Bauman JN, Goosen TC, et al. Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol. 2007 ; 64: 458-468.
33. Anderson PL, Kakuda TN, Lichtenstein KA The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis. 2004 ; 38: 743-753.
34. Fletcher CV, Acosta EP, Henry K., et al. Concentration-controlled zidovudine therapy. Clin Pharmacol Ther. 1998 ; 64: 331-338.
35. Anderson PL, Kakuda TN, Kawle S., Fletcher CV Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS. 2003 ; 17: 2159-2168.
36. Fletcher CV, Kawle SP, Kakuda TN, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS. 2000 ; 14: 2137-2144.
37. Stretcher BN, Pesce AJ, Frame PT, Greenberg KA, Stein DS Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS. 1994 ; 8: 763-769.
38. Rotger M., Csajka C., Telenti A. Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. Curr HIV/AIDS Rep. 2006 ; 3: 118-125.
39. Moore KH, Yuen GJ, Hussey EK, Pakes GE, Eron JJ Jr, Bartlett JA Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother. 1999 ; 43: 3025-3029.
40. Barry M., Mulcahy F., Merry C., Gibbons S., Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999 ; 36: 289-304.
41. BMS. Zerit (stavudine) capsules and oral solution [package insert]. Princeton, NJ: Bristol-Myers Squibb ; 2008.